Next-Generation Cancer Treatment System with Targeted Human Growth Hormone Receptor Antagonists
Legal Citation
Summary of the Inventive Concept
A system for treating cancer with genetically engineered, cancer cell-specific human growth hormone receptor antagonists, enhancing the efficacy of chemotherapeutic agents and improving patient outcomes.
Background and Problem Solved
The original patent disclosed a composition and method for treating cancer using human growth hormone receptor antagonists. However, these antagonists lacked specificity, potentially leading to unwanted side effects. The new inventive concept addresses this limitation by engineering antagonists to selectively bind to cancer cells, reducing off-target effects and improving treatment outcomes.
Detailed Description of the Inventive Concept
The system comprises a genetically engineered human growth hormone receptor antagonist, designed to selectively bind to cancer cells expressing high levels of human growth hormone receptor. This antagonist is administered in coordination with a chemotherapeutic agent, enhancing the efficacy of the treatment. Additionally, the system includes a method for identifying patients likely to respond to this therapy, based on the expression levels of human growth hormone receptor, prolactin receptor, and ABC drug efflux pumps in cancer biopsy samples. A nanoparticle-encapsulated antagonist and a biosensor for monitoring treatment efficacy are also disclosed.
Novelty and Inventive Step
The new claims introduce a paradigm shift in cancer treatment by incorporating genetically engineered, cancer cell-specific antagonists, which is a significant departure from the original patent's composition-based approach. The selective binding of antagonists to cancer cells and the coordination with chemotherapeutic agents are novel and non-obvious aspects of the inventive concept.
Alternative Embodiments and Variations
Alternative embodiments of the system could include the use of different types of nanoparticles or targeted delivery systems for the antagonist, or the incorporation of additional biomarkers for patient selection. Variations of the biosensor could include different detection methods or formats, such as point-of-care devices or lab-based assays.
Potential Commercial Applications and Market
The next-generation cancer treatment system has significant commercial potential in the oncology market, with potential applications in various types of cancer, including breast, lung, and pancreatic cancer. The targeted approach and improved efficacy could lead to increased adoption and market share.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular oncology, protein engineering, targeted cancer therapeutics, with expertise in growth hormone receptor antagonists, protein modification, and targeted drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A molecular biologist or pharmaceutical researcher with advanced degrees in biochemistry or molecular biology, experienced in protein engineering, cancer therapeutics, receptor antagonist design, and targeted drug delivery techniques
Obviousness Rationale
A PHOSITA would recognize that the published technical disclosure represents a predictable extension of the source patent's core technology by applying standard protein engineering and targeted drug delivery techniques to enhance the specificity and efficacy of growth hormone receptor antagonists in cancer treatment. The variations demonstrate routine optimization of the original antagonist concept through well-established molecular biology techniques such as selective genetic modification, nanoparticle encapsulation, and biomarker-guided patient selection. These modifications represent incremental improvements that would be obvious to a skilled practitioner seeking to enhance the therapeutic potential of growth hormone receptor antagonists.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |